Protagonist Therapeutics, Inc (PTGX) Financials
Key financial figures for Protagonist Therapeutics, Inc (Q3 2026).
Q3 2026 license and collaboration revenue was $274.4M, driven by $266.6M of proportional recognition of the $275.0M earned from Takeda on FDA approval of MIMRYLO, lifting net income to $220.0M ($3.07 diluted EPS). License and collaboration revenue was $274.4M versus $4.7M in Q3 2025. The release attributes $266.6M to proportional recognition of the $275.0M earned from Takeda in the quarter (a $200.0M opt-out fee plus a $75.0M milestone triggered by FDA approval of MIMRYLO); $7.8M came from development services under the Takeda agreement and other revenues. Income from operations was $218.3M versus a $46.4M loss a year earlier; net income was $220.0M, or $3.07 per diluted share, versus a $39.3M net loss ($0.62 per share). Income tax expense was $6.6M versus none in Q3 2025. On the outlook: The release gave no revenue or earnings guidance. Management said it expects R&D expense to increase for the remainder of the year compared with the prior quarters in 2026, driven by advancing PN-881 into a Phase 2 psoriasis program, clinical manufacturing and CMC investment, additional pre-clinical discovery programs, and higher headcount and stock-based compensation. Figures are for Q3 2026, as Protagonist Therapeutics, Inc. reported them.
- Revenue
- $274M
- Net Income
- $220M
- EPS
- $3.32
- Total Assets
- $1.1B
- Operating Cash Flow
- -$23M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $274M | $220M | $3.07 | 79.56% | -$23M |
| Q2 FY2026 | $213M | $163M | $2.29 | 74.37% | $219M |
| Q1 FY2026 | $56M | $4M | $0.05 | -6.47% | -$49M |
| Q4 FY2025 | $7M | -$44M | -$0.69 | -677.09% | |
| Q3 FY2025 | $5M | -$39M | -$0.62 | -985.17% | -$2M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $46M | -$130M | -$2.05 | -343.63% | $56M |
| FY2024 | $434M | $275M | $4.23 | 58.2% | $183M |
| FY2023 | $60M | -$79M | -$1.39 | -156.09% | -$71M |
Frequently asked questions
What was Protagonist Therapeutics, Inc.'s revenue last quarter?
Protagonist Therapeutics, Inc. reported revenue of $274.4 million for Q3 FY2026, up 5723.6% from the same period a year earlier.
Is Protagonist Therapeutics, Inc. profitable?
Yes. Protagonist Therapeutics, Inc. reported net income of $220.0 million for Q3 FY2026, a net margin of 80.18% on revenue.
How has Protagonist Therapeutics, Inc.'s margin trended?
Operating margin was 79.56% in Q3 FY2026, compared with -985.17% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Protagonist Therapeutics, Inc. generate?
Protagonist Therapeutics, Inc. generated free cash flow of -$23.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Protagonist Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.